Blood pressure and vascular health markers is closer to a research marker, so it should be read separately from a directly felt benefit.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
The group showed a positive signal, but individual contributions are hard to isolate. Not a stack recommendation.
Paper IDs and full lists are private. Only study types and summaries are shown.
An adequate intake of potassium is desirable to achieve a lower BP level but excessive potassium supplementation should be avoided, particularly in specific subgroups, according to the findings of a meta‐analysis.
Average sodium intake in all age groups across China is approximately double the recommended maximum limits, and potassium intake is less than half that recommended.
Higher sodium intake and higher dietary sodium-to-potassium ratio were associated with a higher risk of stroke and can be considered as a supplementary approach in parallel with the decrease in sodium intake in order to decrease stroke risk.
The findings indicated that potassium supplementation is a safe medication with no important adverse effects that has a modest but significant impact BP and may be recommended as an adjuvant antihypertensive agent for patients with essential hypertension.
The reduced-sodium added-potassium salt led to a substantial reduction in systolic BP in hypertensive patients, supporting salt substitution as an effective, low-cost intervention for BP lowering in rural India.
Global mean potassium intake falls below current guideline recommended intake level of > 3.5 g/day, with only 14% (95% CI 11–17%) of the global population achieving guideline-target mean intake.